20:04 , Jan 18, 2019 |  BC Week In Review  |  Company News

Proteus launches digital oral chemo management system

Proteus Digital Health Inc. (Redwood City, Calif.) launched a digital cancer medicine system to help manage oral chemotherapy treatment of stage 3 and 4 colorectal cancer patients. The system, which was developed with the University...
13:46 , Jan 16, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Cell culture and mouse studies identified a naphthalenone-based Hsp90 inhibitor that could help treat glioblastoma. Screening of a small molecule library in a HeLa cell-based activity assay, followed by optimization and in...
18:13 , Jan 11, 2019 |  BC Week In Review  |  Company News

Click, Otsuka partner on digital therapy for depression

Click Therapeutics Inc. (San Francisco, Calif.) partnered with Otsuka America Inc. to develop and commercialize CT-152, a digital therapy to treat major depressive disorder (MDD). Otsuka said it will pay Click up to $10 million...
01:07 , Jan 8, 2019 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Anxiety Mouse studies suggest depleting senescent cells could help treat obesity-induced anxiety. In a transgenic mouse model of obesity expressing the senescence marker human CDKN2A, a tool compound that depletes CDKN2A-positive cells decreased anxiety-like...
01:06 , Jan 8, 2019 |  BC Innovations  |  Distillery Therapeutics

Transplant

INDICATION: Heart transplant rejection; graft rejection Mouse studies suggest inhibiting CORO1A or its downstream mediator PDE-4 could help treat heart transplant and skin graft rejection. In a mouse model of heart transplantation, systemic CORO1A knockout...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
19:27 , Dec 21, 2018 |  BC Week In Review  |  Company News

Otsuka's Avanir to terminate Onzetra license

OptiNose Inc. (NASDAQ:OPTN) said it received written notice from Avanir Pharmaceuticals Inc. that the latter intends to terminate, effective March 10, a license granting it rights to develop and commercialize migraine drug Onzetra Xsail in...
20:48 , Dec 19, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest inhibiting the BRD4-FOXO3-CDK6 axis could help treat luminal breast cancer resistant to AKT inhibitors. In patients who had been treated for hormone receptor-positive luminal...
22:24 , Dec 13, 2018 |  BC Extra  |  Company News

Management tracks: Ambys, Foghorn

Liver regenerative medicine company Ambys Medicines (Redwood City, Calif.) hired Jeff Jonker as president, CEO and a director. He succeeds Interim CEO Jeffrey Tong, who will become chairman. Jonker was president of NGM Biopharmaceuticals Inc....
01:42 , Dec 13, 2018 |  BC Extra  |  Company News

Management tracks: Tamura reclaims CEO role at Sosei

Sosei Group Corp. (Tokyo:4565) said Peter Bains will step down as president and CEO and resign as director on Dec. 31. Executive Chairman, founder and former CEO Shinichi Tamura will replace Bains, effective Jan. 1....